Arcellx, Inc.
Clinical trials sponsored by Arcellx, Inc., explained in plain language.
A clinical-stage biotechnology company developing cell therapies for cancer and autoimmune diseases.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- Can engineered immune cells outsmart Hard-to-Treat blood cancers? Results expected Oct 2026 (estimated)
- Could CAR t-cells tame myasthenia gravis? early trial launches Results expected Mar 2027 (estimated)